JHMC’s cancer drug Camrelizumab is unaffordable, being pricier than its competitor

JHMC’s cancer drug Camrelizumab is unaffordable, being pricier than its competitor
Unsplash Photo by National Cancer Institute
Written by
Reviewed by
Luca L.

Register to read the full analysis —or— Upgrade to access more features

#cost #price #pricing #returns

Actual Direct Impact

Assess the impact materiality of this Topic for Jiangsu Hengrui Medicine

How negative/positive is the impact of Jiangsu Hengrui Medicine for this Topic?

How would you rate the severity of this impact?

Share this Analysis


Written by
Reviewed by
Luca L.

Keen to rectify an issue with this analysis?